Validation of Lysyl Oxidase-Like 2 (LOXL2) as Prognostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) Using an Independent Cohort. Abstract #1316

Introduction: LOXL2 is a key protein to epithelial to mesenchymal transition. We showed LOXL2 has a role as a prognostic marker in 115 GEP-NET cases (training cohort (TC)).
Aim(s): Validation of LOXL2 expression by immunohistochemistry (IHC) in an independent cohort.
Materials and methods: Formalin-fixed paraffin-embedded samples (FFPE) of consecutive GEP-NET patients from 1999 to 2010 who underwent surgery in a different Spanish institution constituted the validation cohort (VC). Tissue microarrays were constructed from 2 non-necrotic areas of tumour foci. LOXL2 expression was studied by IHC and classified as presence (P) vs absence (A). Log rank test and Cox regression were used to study Disease Free Survival (DFS) and Overall Survival (OS). Univariate and multivariable analysis (MVA) were performed.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Jorge Barriuso
Keywords: LOXL2

To read results and conclusion, please login ...

Further abstracts you may be interested in

#966 Evaluation of Lysyl Oxidase-Like-2 (LOXL2) Expression by Immunohistochemistry (IHC) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): A Retrospective Analysis and Comparison with PTEN
Introduction: A better understanding of the relationship between the stroma and the cancer cells of this group of malignancies remains a challenge. LOXL2 is an enzyme that contributes to the synthesis and stabilization of the cellular matrix and plays a role in angiogenesis.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Dr Jorge Barriuso
Keywords: LOXL2, GEP-NET
#1492 Prospective Validation of Prognostic Score in High-Grade Gastrointestinal Neuroendocrine Carcinomas (GI-NECs)
Introduction: Prognostic markers for risk-stratification of GI-NECs are lacking.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Angela Lamarca
#1680 PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs).
Introduction: Treatment options for patients with advanced Wd SB-NETs are limited.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Angela Lamarca
Keywords: immunotherapy
#1813 Determination of an Optimal Response Cut-Off to Predict Progression-Free Survival(PFS) in Patients(pts) with Well-Differentiated Advanced Pancreatic Neuroendocrine Tumours(pNETs) Treated with Sunitinib(S): An Alternative to the Current RECIST-Response
Introduction: Sunitinib prolongs PFS in pNET; RECIST defined-partial responses (PR; ≥30% decrease) are low.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Angela Lamarca
Keywords: sunitinib, RECIST, cut-off
#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).
Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso